Cargando…
Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in various human cancer diseases. Recently, the first compounds received FDA approval in biomarker-selected patient populations. Different approaches and technologies have been applied in clinical trials, ranging...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563413/ https://www.ncbi.nlm.nih.gov/pubmed/36231142 http://dx.doi.org/10.3390/cells11193180 |